Published in Eur J Biochem on November 01, 1988
Interleukin-6 and the acute phase response. Biochem J (1990) 7.97
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest (1991) 3.62
Circulating interleukin-6 mediates the febrile response to localised inflammation in rats. J Physiol (2000) 1.75
Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol (2008) 1.64
Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch Dis Child Fetal Neonatal Ed (1997) 1.63
Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage*. Crit Care Med (2012) 1.51
Maternal microbe-specific modulation of inflammatory response in extremely low-gestational-age newborns. MBio (2011) 1.42
Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol (2004) 1.37
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer (2009) 1.29
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A (2005) 1.25
Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression in human hepatocytes. J Exp Med (1989) 1.13
Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol (2002) 1.08
Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery. Crit Care (2010) 1.06
Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation (1994) 1.06
Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol (1991) 1.05
Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest (1990) 1.02
Relationships among the concentrations of 25 inflammation-associated proteins during the first postnatal weeks in the blood of infants born before the 28th week of gestation. Cytokine (2011) 1.02
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res (1995) 0.96
Exercise-induced liver chemokine CXCL-1 expression is linked to muscle-derived interleukin-6 expression. J Physiol (2011) 0.90
The effect of acute intermittent hypercapnic hypoxia treatment on IL-6, TNF-alpha, and CRP levels in piglets. Sleep (2007) 0.88
Modeling the NF-κB mediated inflammatory response predicts cytokine waves in tissue. BMC Syst Biol (2011) 0.86
Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy. Nephrol Dial Transplant (2012) 0.86
Source and kinetics of interleukin-6 in humans during exercise demonstrated by a minimally invasive model. Eur J Appl Physiol (2010) 0.86
Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients. World J Gastroenterol (2007) 0.85
Subcutaneous adipose tissue from obese and lean adults does not release hepcidin in vivo. ScientificWorldJournal (2011) 0.84
In vivo changes in plasma acute phase protein levels in the rat induced by slow release of IL-1, IL-6 and TNF. Mediators Inflamm (1992) 0.84
Extent of the acute phase response in fulminant hepatic failure. Gut (1994) 0.83
Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J (1991) 0.82
Gut and liver handling of interleukin-6 during liver resection in man. HPB (Oxford) (2011) 0.80
Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta. Biomed Res Int (2015) 0.78
A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats. J Zhejiang Univ Sci B (2011) 0.78
Improved fracture healing in patients with concomitant traumatic brain injury: proven or not? Mediators Inflamm (2015) 0.78
Change in cardiovascular risk factors with progression of kidney disease. Am J Nephrol (2008) 0.77
Pharmacokinetics of natural and engineered secreted factors delivered by mesenchymal stromal cells. PLoS One (2014) 0.76
Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". Toxins (Basel) (2017) 0.75
Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling. Sci Rep (2017) 0.75
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nat Commun (2017) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Engineered GFP as a vital reporter in plants. Curr Biol (1996) 9.03
Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 8.85
Interleukin-6 and the acute phase response. Biochem J (1990) 7.97
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
Identification of Xenopus SMC protein complexes required for sister chromatid cohesion. Genes Dev (1998) 5.78
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem (1987) 4.99
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34
Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med (1999) 4.33
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 4.25
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
ATP-dependent positive supercoiling of DNA by 13S condensin: a biochemical implication for chromosome condensation. Cell (1997) 3.95
Phosphorylation and activation of 13S condensin by Cdc2 in vitro. Science (1998) 3.89
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res (2000) 3.86
Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology (1998) 3.82
Molecular regulation of B lymphocyte response. Annu Rev Immunol (1988) 3.68
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 3.66
Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59
Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A (1985) 3.46
Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology (2000) 3.46
A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J (1996) 3.40
Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol (1993) 3.37
Molecular structure of human lymphocyte receptor for immunoglobulin E. Cell (1986) 3.34
Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn (1999) 3.33
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (1990) 3.27
IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol (2003) 3.26
13S condensin actively reconfigures DNA by introducing global positive writhe: implications for chromosome condensation. Cell (1999) 3.24
Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology (1992) 3.17
IL-6 is produced by osteoblasts and induces bone resorption. J Immunol (1990) 3.14
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13
Chemical nature of the light emitter of the Aequorea green fluorescent protein. Proc Natl Acad Sci U S A (1996) 3.12
IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol (2000) 3.08
Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun (1999) 3.03
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Analysis of upstream elements in the HuC promoter leads to the establishment of transgenic zebrafish with fluorescent neurons. Dev Biol (2000) 2.93
LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science (1993) 2.93
HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet (1992) 2.93
Identification and characterization of SA/Scc3p subunits in the Xenopus and human cohesin complexes. J Cell Biol (2000) 2.91
Non-invasive quantitative detection and applications of non-toxic, S65T-type green fluorescent protein in living plants. Plant J (1999) 2.88
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell (1992) 2.83
Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet (1995) 2.81
IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev (1992) 2.80
Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J (1997) 2.80
Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology (2002) 2.80
AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1990) 2.79
Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett (1989) 2.79
Factors affecting B-cell growth and differentiation. Annu Rev Immunol (1985) 2.78
Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A (1987) 2.76
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75